Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Rallybio (RLYB) Gains from Investment Securities (2022 - 2023)

Rallybio's Gains from Investment Securities history spans 2 years, with the latest figure at $146500.0 for Q1 2023.

On a quarterly basis, Gains from Investment Securities changed N/A to $146500.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $146500.0, a N/A change, with the full-year FY2022 number at $2.6 million, changed N/A from a year prior.
Gains from Investment Securities hit $146500.0 in Q1 2023 for Rallybio, down from $2.6 million in the prior quarter.
Over the last five years, Gains from Investment Securities for RLYB hit a ceiling of $2.6 million in Q4 2022 and a floor of $146500.0 in Q1 2023.